Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.
Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fätkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H. Rockstroh JK, et al. Among authors: fenske s. AIDS. 2000 Jun 16;14(9):1181-5. doi: 10.1097/00002030-200006160-00015. AIDS. 2000. PMID: 10894282 Clinical Trial.
Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.
Lichterfeld M, Nischalke HD, Bergmann F, Wiesel W, Rieke A, Theisen A, Fätkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H, Wasmuth JC, Rockstroh JK. Lichterfeld M, et al. Among authors: fenske s. HIV Med. 2002 Jan;3(1):37-43. doi: 10.1046/j.1464-2662.2001.00091.x. HIV Med. 2002. PMID: 12059949 Free article. Clinical Trial.
The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.
Vogel M, Ahlenstiel G, Hintsche B, Fenske S, Trein A, Lutz T, Schürmann D, Stephan C, Khaykin P, Bickel M, Mayr C, Baumgarten A, Buggisch P, Klinker H, John C, Gölz J, Staszewski S, Rockstroh JK. Vogel M, et al. Among authors: fenske s. Eur J Med Res. 2010 Mar 30;15(3):102-11. doi: 10.1186/2047-783x-15-3-102. Eur J Med Res. 2010. PMID: 20452894 Free PMC article. Clinical Trial.
Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).
Stellbrink HJ, van Lunzen J, Westby M, O'Sullivan E, Schneider C, Adam A, Weitner L, Kuhlmann B, Hoffmann C, Fenske S, Aries PS, Degen O, Eggers C, Petersen H, Haag F, Horst HA, Dalhoff K, Möcklinghoff C, Cammack N, Tenner-Racz K, Racz P. Stellbrink HJ, et al. Among authors: fenske s. AIDS. 2002 Jul 26;16(11):1479-87. doi: 10.1097/00002030-200207260-00004. AIDS. 2002. PMID: 12131185 Clinical Trial.
Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort.
Stoll M, Kollan C, Bergmann F, Bogner J, Faetkenheuer G, Fritzsche C, Hoeper K, Horst HA, van Lunzen J, Plettenberg A, Reuter S, Rockstroh J, Stellbrink HJ, Hamouda O, Bartmeyer B; ClinSurv Study Group. Stoll M, et al. PLoS One. 2011;6(9):e23946. doi: 10.1371/journal.pone.0023946. Epub 2011 Sep 9. PLoS One. 2011. PMID: 21931626 Free PMC article.
Interleukin-2 therapy in patients with HIV infection.
INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee; Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. INSIGHT-ESPRIT Study Group, et al. N Engl J Med. 2009 Oct 15;361(16):1548-59. doi: 10.1056/NEJMoa0903175. N Engl J Med. 2009. PMID: 19828532 Free PMC article. Clinical Trial.
105 results